Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chelation therapy for iron overload.

James C Barton1

  • 1Southern Iron Disorders Center, G-105, 2022 Brookwood Medical Center Drive, Birmingham, AL 35243, USA. ironmd@dnamail.com

Current Gastroenterology Reports
|March 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimates of European Ancestry in U.S. Hispanics Using <i>HFE</i> p.C282Y (c.845G>A; rs1800562), a Highly Informative Autosomal Marker.

Genetic testing and molecular biomarkers·2026
Same author

Serum IgA and IgM levels in hemochromatosis probands with HFE p.C282Y homozygosity.

PloS one·2026
Same author

A Decreasing North-to-South Gradient of <i>HFE</i> p.C282Y (rs1800562) Allele Frequencies in Iberia: An Analysis of 34 Population/Control Cohorts.

Genes·2026
Same author

Mean Corpuscular Volume in <i>HFE</i> p.C282Y/p.H63D Compound Heterozygotes With High Iron Phenotypes: Clinical and Laboratory Associations.

Journal of hematology·2026
Same author

Comparisons of iron phenotypes and reports of menses, pregnancies, and live births in women with <i>HFE</i> p.C282Y homozygosity and <i>HFE</i> wt/wt.

medRxiv : the preprint server for health sciences·2026
Same author

Macrocyte subpopulations in hemochromatosis probands with HFE p.C282Y homozygosity: Clinical and laboratory associations.

The American journal of the medical sciences·2026
Same journal

Management of Common Bile Duct Stones: Current Approaches and Evolving Endoscopic Strategies.

Current gastroenterology reports·2026
Same journal

Solitary Rectal Ulcer Syndrome Revisited: A Comprehensive Narrative Review.

Current gastroenterology reports·2026
Same journal

The Microbiome and Esophageal Disease: Where Are We Now?

Current gastroenterology reports·2026
Same journal

Fermented Durian Tempoyak as a Source of Probiotics for Colorectal Cancer Prevention through Gut Microbiome Modulation.

Current gastroenterology reports·2026
Same journal

A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.

Current gastroenterology reports·2026
Same journal

The Role of Endoscopic Ultrasound in the Diagnosis and Management of Congenital Gastrointestinal and Pancreaticobiliary Conditions.

Current gastroenterology reports·2026
See all related articles

Iron overload causes organ damage, necessitating effective chelation therapy. New oral iron chelators offer improved management options for various iron overload conditions, including anemias and hemochromatosis.

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Iron overload leads to significant organ damage in the heart, liver, and endocrine glands.
  • Limited physiological mechanisms exist for iron excretion, making therapeutic intervention crucial.

Purpose of the Study:

  • To review current and emerging iron chelation therapies for managing iron overload.
  • To discuss therapeutic alternatives for patients with hereditary anemias and hemochromatosis.

Main Methods:

  • Review of licensed iron chelation drugs (parenteral and oral).
  • Assessment of ongoing clinical investigations for novel oral chelators.
  • Analysis of therapeutic strategies for diverse iron overload etiologies.

Main Results:

Related Experiment Videos

  • Three licensed iron chelation drugs are available: one parenteral and two oral.
  • Development and investigation of additional oral chelators are expanding treatment options.
  • Chelation therapy presents alternatives to phlebotomy for specific patient groups.

Conclusions:

  • Effective iron chelation is vital for preventing organ damage in iron overload disorders.
  • Emerging oral chelators enhance management strategies for beta-thalassemia major, sickle cell disease, and hemochromatosis.
  • Therapeutic advancements provide crucial alternatives for patients with various iron overload conditions.